Navigation Links
Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia
Date:12/8/2009

inib Efficacy and Safety in Clinical Trials of Newly Diagnosed Ph+ CML Patients (ENESTnd), is a Phase III randomised, open-label, multicentre trial comparing the efficacy and safety of nilotinib versus imatinib in adult patients with newly diagnosed Ph+ CML in the chronic phase.(1) It is the largest global randomised comparison of two oral therapies ever conducted in newly diagnosed Ph+ CML patients.

ENESTnd is being conducted at 220 global sites, including five sites in the UK, in total 846 patients are enrolled. Patients were randomised to receive nilotinib 400mg twice-daily (n = 281), nilotinib 300mg twice-daily (n = 282) or imatinib 400mg once-daily (n = 283).(1) The primary endpoint was MMR at 12 months; a secondary endpoint was CCyR by 12 months. It is planned that patients are followed up for five years. Patients on the imatinib treatment arm who had suboptimal response or treatment failure will be able to escalate dose and/or switch to nilotinib via a protocol extension.

One of the key effectiveness measures used in the study was called major molecular response (MMR). This is defined as the reduction in levels of the Bcr-Abl protein to less than or equal to 0.1% of the level seen before treatment. MMR is an important measure in CML, as data show that patients who achieve MMR are unlikely to progress to the later stages of the disease.(6) With nilotinib 300mg twice-daily, the rate of MMR at 12 months was twice that of patients receiving imatinib 400mg once-daily (44% vs. 22%, p < 0.0001).(1)

Another effectiveness measure used in the study was called complete cytogenetic response (CCyR). CCyR indicates that no CML cells containing the Ph chromosome can be seen in a sample of bone marrow taken from the patient. 80% of patients achieved CCyR with nilotinib versus 65% with imatinib 400mg once-daily (p < 0.0001).(1) Responses were achieved faster in the nilotinib group than in the imatinib group.(1)

'/>"/>
SOURCE Novartis Oncology
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
3. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
4. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
5. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
6. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
7. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
8. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
9. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
10. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
11. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... , Sept. 17, 2014  Trovagene, Inc., (NASDAQ: ... today that Alberto Bardelli , Ph.D., has joined ... the first to identify mutations in the kinase genes ... Currently, he is at the Department of Oncology, Torino ... Italy . "Alberto,s work ...
(Date:9/17/2014)...  Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL ), ... received an unsolicited, non-binding proposal from Endo International plc ... the outstanding shares of Auxilium common stock at a ... stock, subject to due diligence, financing and other conditions. ... received from Endo on Friday evening is reproduced below. ...
(Date:9/17/2014)... , Sept. 17, 2014 Research ... "Global Breast Cancer Market 2014-2018" report to ... by the uncontrolled growth of cancerous cells in the ... however, male breast cancer is rare. Histologically, breast cancer ... cancer and other undifferentiated carcinoma. Ductal carcinoma is the ...
Breaking Medicine Technology:Cancer Geneticist, Alberto Bardelli, Ph.D., Joins Trovagene's Scientific Advisory Board 2Cancer Geneticist, Alberto Bardelli, Ph.D., Joins Trovagene's Scientific Advisory Board 3Auxilium Responds To Unsolicited Proposal From Endo International 2Auxilium Responds To Unsolicited Proposal From Endo International 3Auxilium Responds To Unsolicited Proposal From Endo International 4Auxilium Responds To Unsolicited Proposal From Endo International 5Auxilium Responds To Unsolicited Proposal From Endo International 6Auxilium Responds To Unsolicited Proposal From Endo International 7Global Breast Cancer Market 2014-2018: Key Vendors are Astrazeneca, Eli Lilly and Company and F. Hoffmann-La Roche, Novartis and Sanofi-Aventis 2Global Breast Cancer Market 2014-2018: Key Vendors are Astrazeneca, Eli Lilly and Company and F. Hoffmann-La Roche, Novartis and Sanofi-Aventis 3
... (OTC Bulletin Board: CGNH ) announced today that ... 2 Class B common stockholders a "Stockholder Questionnaire," which the ... count of the Company,s shares currently held in "street ... If you have not received the Stockholder Questionnaires via ...
... VILLAGE, Nev., March 8, 2011 PDL BioPharma, Inc. (PDL) (Nasdaq: ... rate for its 2.00% Convertible Senior Notes due February 15, 2012 ... 15, 2015 (the 2015 Notes) effective March 7, 2011, in connection ... to all stockholders who own shares of PDL on March 8, ...
Cached Medicine Technology:CardioGenics Requests Stockholders to Participate in Stockholder Questionnaires 2PDL BioPharma Announces Conversion Rate Adjustments for 2.00% Convertible Senior Notes Due February 15, 2012 and 2.875% Convertible Senior Notes Due February 15, 2015 2
(Date:9/17/2014)... September 17, 2014 In ongoing ... Inc.’s Drug Benefit News (DBN) continues to find ... in its Aug. 8 issue , CVS Caremark ... lists for 2015 each cut more drugs than ... savings these exclusions are likely to achieve. Despite ...
(Date:9/17/2014)... Washington, DC (PRWEB) September 17, 2014 ... family history. Along with regular screening and examination, a ... In this episode of Epicure with the Chef ... GWMFA Urologist Dr. Paul Rusilko to prepare a delicious ... in our western diets that influence risk of prostate ...
(Date:9/17/2014)... 2014 “North America Gynecological Devices ... on the North America Gynecological Devices market. The ... volume (in units) and average prices (in US ... Female Sterilization Devices (Transcervical Sterilization Devices (Micro-inserts) ... , Endometrial Ablation Devices (Thermal Balloon, ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 Stand Up ... and music, returns to the Theater at Madison Square ... the Bob Woodruff Foundation (BWF) and New York Comedy ... returning service members, veterans and their families. , ... John Mulaney, John Oliver, Bruce Springsteen, Brian Williams and ...
(Date:9/17/2014)... Alpharetta, GA (PRWEB) September 17, 2014 ... Background Screeners (NAPBS®) Background Screening Credentialing Council ... demonstrated compliance with the Background Screening Agency ... formally recognized as BSCC-Accredited. , S2Verify, ... , Each year, U.S. employers, organizations and ...
Breaking Medicine News(10 mins):Health News:AIS Newsletter Continues to Find Industry Criticism of PBM Formulary Exclusion Lists 2Health News:AIS Newsletter Continues to Find Industry Criticism of PBM Formulary Exclusion Lists 3Health News:Boost Prostate Health with Epicure with the Chef MDs 2Health News:Gynecological Devices Market in North America (US, Canada & Mexico) to 2020 New Report Available at MarketOptimizer.org 2Health News:Gynecological Devices Market in North America (US, Canada & Mexico) to 2020 New Report Available at MarketOptimizer.org 3Health News:Gynecological Devices Market in North America (US, Canada & Mexico) to 2020 New Report Available at MarketOptimizer.org 4Health News:Louis C.K., John Mulaney, John Oliver, Bruce Springsteen, Brian Williams & More to Perform at 8th Annual Stand Up for Heroes at Theater at Madison Square Garden, Nov. 5 2Health News:Louis C.K., John Mulaney, John Oliver, Bruce Springsteen, Brian Williams & More to Perform at 8th Annual Stand Up for Heroes at Theater at Madison Square Garden, Nov. 5 3Health News:Louis C.K., John Mulaney, John Oliver, Bruce Springsteen, Brian Williams & More to Perform at 8th Annual Stand Up for Heroes at Theater at Madison Square Garden, Nov. 5 4Health News:Louis C.K., John Mulaney, John Oliver, Bruce Springsteen, Brian Williams & More to Perform at 8th Annual Stand Up for Heroes at Theater at Madison Square Garden, Nov. 5 5Health News:S2Verify Achieves Background Screening Credentialing Council Accreditation 2Health News:S2Verify Achieves Background Screening Credentialing Council Accreditation 3
... , , COLCHESTER, ... College of Pharmacy and Health Sciences opened its Vermont Satellite Campus ... in scenic Colchester, Vermont, is home to the only pharmacy program ... campus offers a four year program culminating in a Doctor of ...
... ... Eye Institute of Utah – a prominent Salt Lake City, Utah ... a national award recognizing the quality of its work. Known as one of ... Springs, Wyoming location has been named by the U.S. Commerce Association as one ...
... U.S. Commerce ... living with Diabetes. , ... Raton, FL (PRWEB) August 31, 2009 -- Leading provider of diabetes medical supplies, American Diabetes ... Medical Supplies category by the U.S. Commerce Association (USCA). The company is aiding those ...
... ... solution to address current challenges in public health reporting and to improve the early detection, ... , ... 2009 -- Orion Health, Inc. and Cisco today announced the Rhapsody® ...
... , , MAASTRICHT, ... VAR ) is introducing the world,s first low-energy radiotherapy ... clinics. Varian,s UNIQUE(TM) radiotherapy system is expected to make advanced ... around the world. , , "This package ...
... , , NUTLEY, N.J., ... that the U.S. Food and Drug Administration (FDA) has approved Valcyte(R) ... kidney and heart transplant patients (4 months to 16 years of ... also approved a new pediatric oral solution formulation for Valcyte, which ...
Cached Medicine News:Health News:Albany College of Pharmacy and Health Sciences Opens Vermont Satellite Campus 2Health News:The Eye Institute Receives 2009 Best of Rock Springs Award from U.S. Commerce Association 2Health News:The Eye Institute Receives 2009 Best of Rock Springs Award from U.S. Commerce Association 3Health News:Provider of Diabetes Medical Supplies Receives 2009 Best of Boca Raton Award 2Health News:Orion Health and Cisco Announce New Medical Data Exchange Solution to Integrate, Share and Report Public Health Data 2Health News:Orion Health and Cisco Announce New Medical Data Exchange Solution to Integrate, Share and Report Public Health Data 3Health News:Orion Health and Cisco Announce New Medical Data Exchange Solution to Integrate, Share and Report Public Health Data 4Health News:Varian Medical Systems Adds RapidArc(R) and Image Guidance to New Low Energy Treatment Platform for Radiation Therapy in International Cancer Clinics 2Health News:Varian Medical Systems Adds RapidArc(R) and Image Guidance to New Low Energy Treatment Platform for Radiation Therapy in International Cancer Clinics 3Health News:FDA Approves Valcyte(R) (valganciclovir hydrochloride) to Prevent Cytomegalovirus (CMV) Disease in Pediatric Patients Who Receive Heart or Kidney Transplants 2Health News:FDA Approves Valcyte(R) (valganciclovir hydrochloride) to Prevent Cytomegalovirus (CMV) Disease in Pediatric Patients Who Receive Heart or Kidney Transplants 3Health News:FDA Approves Valcyte(R) (valganciclovir hydrochloride) to Prevent Cytomegalovirus (CMV) Disease in Pediatric Patients Who Receive Heart or Kidney Transplants 4
... protection, our conventional aprons are ... sturdy 2 webbed straps that ... hook fasteners. The straps can ... the apron. Our conventional apron ...
Unshielded...
... Triage BNP Test is the first ... measuring B-type natriuretic peptide (BNP) ,Cardiac ... in response to ventricular volume expansion ... of ventricular systolic and diastolic dysfunction. ...
... MOST Options System is designed to ... of the knee or hip to ... provides the potential for restoration of ... the requirements of a rotating hinge ...
Medicine Products: